Sandy Geeganage

Sandy Geeganage has a diverse range of work experience in the pharmaceutical and academic sectors. Sandy is currently serving as the Vice President of Drug Discovery at Prelude Therapeutics since November 2021. Prior to that, they held the position of Executive Director of Target Discovery at Incyte from May 2020 to November 2021.

Sandy also has extensive experience at Eli Lilly and Company, where they held various roles in Oncology Discovery. From October 2016 to May 2020, they worked as a Research Fellow. Sandy also served as Group Leader, Cancer Signaling and Metabolism from December 2009 to May 2020, Senior Research Advisor in Oncology Discovery from November 2010 to September 2016, Research Advisor from November 2008 to October 2010, Principal Research Scientist from November 2005 to October 2008, Senior Research Scientist from November 2004 to October 2005, and Research Scientist from November 2000 to October 2004.

Before their tenure at Eli Lilly and Company, Sandy worked as a Postdoctoral Research Fellow at the University of Wisconsin-Madison from July 1999 to November 2000. Sandy also completed their Graduate Studies at the same university from 1994 to 1999.

Sandy Geeganage completed a PhD in Biochemistry from the University of Wisconsin-Madison in the years 1994 to 1999. Prior to that, they pursued a Bachelor of Science degree in Chemistry from The University of the South between 1990 and 1994. Sandy also attended the Royal College from 1975 to 1987, although no specific degree or field of study was provided for this period.